Compare Emerson Electric Co. (EMR) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Zoetis Inc — how do they compare? Emerson Electric Co. trades at $161.97 (market cap $88.72B), while Zoetis Inc trades at $74.36 (market cap $30.20B). The key difference: Emerson Electric Co. is far larger — about 2.9× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and Zoetis Inc for 70 Days on average.
| EMR | ZTS | |
|---|---|---|
Market Cap | $88.72B | $30.20B |
Volume | 2,355,255 | 6,175,327 |
Sector | Industrials | Health |
52-Week High | $164.38 | $147.53 |
52-Week Low | $123.30 | $69.09 |
Typical Hold Time | 81 Days | 70 Days |
Enterprise Value | $99.80B | $37.76B |
Dividend Yield | 1.4% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $161.13, up 1.2% today, with a bullish technical trend and strong quarterly earnings beats. The stock is supported by a 53.49% analyst buy consensus and a $165.90 price target. Revenue growth is steady, with 2025 revenue at $18.02B and net income of $2.29B, while profitability metrics like a 13.83% net margin and 12.81% ROE reflect operational strength. Recent news highlights momentum and Wall Street optimism, though valuation multiples like a P/E of 34.81 suggest premium pricing.
EMR's outlook is positive, driven by earnings momentum and analyst confidence, but risks include elevated valuation and debt levels. The stock offers growth potential with a dividend, yet investors face headwinds from competitive pressures and economic cycles. Upside to the consensus target implies modest gains, balancing fundamental strength with valuation concerns.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
